TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer.
- DOI
- 10.1016/j.esmoop.2026.108247
- Published
- 2026 Jul
- Container
- ESMO open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2026.108247,
title = {TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer.},
author = {Schlam I and Trapani D and Kim SE and Heiling H and Faggen M and Sinclair N and Sanz-Altamira P and Battelli C and Berwick S and Lo S and Acevedo J and Sinclair S and Malcolm A and Varella L and Sammons S and Schumer S and Poorvu PD and Wallace E and Pasternak E and Tayob N and Tolaney SM and Mayer EL},
year = {2026},
journal = {ESMO open},
doi = {10.1016/j.esmoop.2026.108247},
url = {https://doi.org/10.1016/j.esmoop.2026.108247}
}RIS
TY - JOUR TI - TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer. AU - Schlam I AU - Trapani D AU - Kim SE AU - Heiling H AU - Faggen M AU - Sinclair N AU - Sanz-Altamira P AU - Battelli C AU - Berwick S AU - Lo S AU - Acevedo J AU - Sinclair S AU - Malcolm A AU - Varella L AU - Sammons S AU - Schumer S AU - Poorvu PD AU - Wallace E AU - Pasternak E AU - Tayob N AU - Tolaney SM AU - Mayer EL PY - 2026 JO - ESMO open DO - 10.1016/j.esmoop.2026.108247 UR - https://doi.org/10.1016/j.esmoop.2026.108247 ER -
APA
I, S., D, T., SE, K., H, H., M, F., N, S., P, S., C, B., S, B., S, L., J, A., S, S., A, M., L, V., S, S., S, S., PD, P., E, W., E, P., N, T., SM, T., & EL, M. (2026). TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer.. ESMO open. https://doi.org/10.1016/j.esmoop.2026.108247
Source records
- pubmed · retrieved 2026-09-25T08:16:14.489Z